News

NUS Oral Vaccine Revolutionizes Fish Health Management

NUS Oral Vaccine Revolutionizes Fish Health Management

Turning the Tide in Aquaculture

Every so often, a scientific breakthrough comes along that could potentially change the fabric of an industry. When it comes to aquaculture, which brings a significant portion of seafood to our tables, the stakes couldn't be higher. The National University of Singapore (NUS) and their buddies over at Temasek Life Sciences Laboratory have thrown their hat in the ring with something big—a groundbreaking oral vaccine to combat the nerve-wracking nervous necrosis virus (NNV) in fish.

The Aquaculture Riddle

On any given day, the aquaculture industry keeps the world’s seafood supply ticking. It's a vital cog in the global food machine. Yet, it faces a gnarly challenge in the form of the nervous necrosis virus. This little bugger can cripple fish populations faster than a whirlpool dragging larvae and fingerlings to their doom with near 100% mortality rates. Traditional vaccination strategies have been a bureaucratic nightmare—injecting fish one by one, stressing them out with needles and human runarounds.

A Vaccine That Feeds

Here's what we’ve been waiting for: a vaccine that fish can simply chow down as part of their regular feeding routine. The NUS and Temasek teams crafted an oral vaccine that isn't just feasible; it's a game changer. Mixing this into fish feed gets the job done without the labor-intensive process of jabbing fishes left and right.

"Our novel discovery of a viable and effective delivery system to transport virus-like particles to enable fish to resist the effects of NNV addresses this pertinent issue," said Prof Yang Daiwen.

So how does it work? Well, it’s all about using Virus-Like Particles (VLPs) acting as the wolf in sheep’s clothing. These imposters engage the fish's immune system, provoking it into gear without the risk of actually making the fish sick. Partnered with the trusty Lactococcus lactis as its sherpas, these VLPs travel through the digestive system to stir an immune frenzy right in the gut.

The Brains Behind the Bacteria

Turning science fiction into fish-saving fact wasn’t just about tossing the bacteria and VLPs together and calling it a day. The researchers, led by the savvy Professor Yang, fine-tuned the formula to make sure those VLPs get where they need to be with all the vigor of a seasoned marathoner. They fiddled around with live and heat-treated bacteria, using sodium hypochlorite to make sure the VLPs stayed intact. The results? Two-fold improvements in antibody levels and staggering reductions in viral replication post-exposure. We're talking a 300 times reduction in the virus hanging out in fish brains.

Patent and Partnership Potential

The ink's not dry yet, but they've filed three patents covering this nifty innovation. The oral vaccine's potential for fish species like groupers and seabasses is enormous. Imagine saving those stocks from mass wipeouts and hemorrhaging economic losses. All that’s left is joining forces with industry partners to test this bad boy in the field—think field trials, scaling up, and industry rollouts.

With these plans afoot, the vision of a more robust, disease-resilient aquaculture industry isn’t just a fish tale. It’s becoming a reality, setting the stage for healthier seafood supplies and fortified industry profit margins. I can't help but wonder, what will these eggheads tackle next?

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

Likang's Bold Move: Cancer Immunotherapy at AD Summit

Updated Category News Views 159

Cancer Care Takes Center Stage Kicking off with a bang in Abu Dhabi, Likang Life Sciences has made a splash in the world of personalized cancer immunotherapy. The Abu Dhabi Future Health Summit 2026 served as the backdrop for this bold move, lighting up discussions with their AI-enabled innovations. Likang's showing at the Summit wasn't just another walk in the park—it...

Continue Reading
Ping An's Bold Green Moves Ahead of APEC 2026

Updated Category News Views 92

Ping An's Pitch for Green: Talking the Talk and Walking the Walk? Well, here's something cooking in Shenzhen at the Ping An Finance Center—an international seminar championing green development initiatives. It's all buzz around Ping An Insurance (HKEX: 2318; SSE: 601318) flexing its green muscle, orchestrating conversations right before APEC 2026. Talk about timing....

Continue Reading
ST Engineering iDirect, MBSat Forge Middle East Satellite Hub

Updated Category News Views 118

Satellite Services Take Off in the Middle East Never thought the day would come where the Middle East is on the threshold of leapfrogging satellite tech, but here we are. ST Engineering iDirect just locked arms with MBSat—yep, that's part of the Mohammed Al Barwani Group—to birth a next-gen satellite connectivity service hub in Oman and across surrounding areas....

Continue Reading
Innovent's IBI3001 Shows Promise in Phase 1 Trials

Updated Category News Views 158

Pioneering Path with IBI3001 at ESMO 2026 Navigating through the crowded landscape of oncology trials, Innovent Biologics recently rolled out some riveting Phase 1 clinical data for their new darling, IBI3001. Top brass from Innovent took to the European Society for Medical Oncology (ESMO) Congress stage to lay bare their findings. Obviously, when you're presenting a...

Continue Reading
Johnson & Johnson's JNJ-6143 Shines in Prostate Cancer Study

Updated Category News Views 145

Prostate Cancer's Persistent Challenge No one in the healthcare game needs the reminder: prostate cancer is no walk in the park, especially for those grappling with advanced stages. Now picture this—you're on your sixth treatment, and the cloud is not lifting. It's a battle that never ends, with traditional therapies sometimes barely holding the line. JNJ-6143's New...

Continue Reading
Innovent's IBI354: New Data Spurs Hope for HER2+ BC

Updated Category News Views 98

Innovent Lauds HER2 ADC's Moment at ESMO 2026 Alright, chin up, investors. At the 2026 ESMO Congress, Innovent's throwing down some promising Phase 2 data for their brainchild, IBI354. You hear that name and it's like hearing about a rock star in the making in the oncology world. The potential here isn’t just talk—it's a loud, resounding call for attention. Their...

Continue Reading
CapCut's Role in AI-Assisted Small Biz Marketing

Updated Category News Views 0

In today's fast-paced digital world, small businesses lament the constant hustle to stay relevant online. This juggling act with limited resources often makes effective marketing feel like a high-wire circus performance. Enter AI tools, promising to lighten the load, and CapCut stands out as a game-changer. AI Tools Revolutionizing Small Business Marketing Amid growing...

Continue Reading
What to Expect: Your First Therapy Session Insights

Updated Category News Views 201

Starting With the Unknown: The Therapy Journey Begins Rolling into that first therapy session can feel like walking into a mystery with no clues. You're not alone if it stirs up some nerves—most folks feel the same, especially when it's your first rodeo in mental health support. That's where Cody Luke and David Spencer of Luke and Spencer Behavioral Health, based out in...

Continue Reading
Kelun-Biotech's Sacituzumab Tirumotecan Shows Promise in NSCLC

Updated Category News Views 0

Kelun-Biotech's Recent Breakthrough Grab your coffee, and let's chat about something that might just change the lung cancer treatment game: Kelun-Biotech's sacituzumab tirumotecan, or sac-TMT, showing some serious promise in a Phase III trial. With numbers that could make any investor sit up a little straighter, this study has turned heads at the European Society for...

Continue Reading
Swanson Nexus Pro Launch: Boost for Dietitians

Updated Category News Views 195

Swanson Enters the Education Arena for Nutritionists Swanson Vitamins is mixing things up again! This time, they're launching something called Swanson Vitamins Nexus Pro, aimed squarely at the registered dietitians and licensed nutritionists crowd. Starting out as the place to grab your basic vitamins, Swanson's not resting on their supplement laurels. No, siree. They've...

Continue Reading

Top 5 Most Recently Viewed Articles

Spruce Point's Strong Sell Rating Casts Doubt on Construction Partners

Updated Category News Views 116

Spruce Point's Strong Sell Opinion on Construction Partners Inc Spruce Point Capital Management has recently issued a compelling report regarding Construction Partners Inc (NASDAQ: ROAD), a company recognized for its expertise in infrastructure and road construction. This report voices a strong sell recommendation, reflecting serious concerns over the company's current...

Continue Reading
Celebrating Excellence in Healthcare: Press Ganey's Honorees

Updated Category News Views 344

Celebrating the Executive Human Experience Award Winners Press Ganey, an industry leader dedicated to enhancing healthcare experiences, recently celebrated exceptional achievements in the field. During its annual conference, the Executive Human Experience Awards recognized extraordinary contributions from professionals and organizations that prioritize patient, consumer,...

Continue Reading
Commercial Vehicle Market Growth Driven by Technology Advancements

Updated Category News Views 122

Commercial Vehicle Market Growth and Projections The global commercial vehicle market is on an upward trajectory, with sales expected to reach 3.5 million units by 2025. The anticipated Year-over-Year (YoY) growth of 4.4% from 2024 highlights the increasing demand for medium and heavy commercial vehicles. This trend is being driven by several factors, including...

Continue Reading
Atos Receives Prestigious EcoVadis Platinum Medal Again

Updated Category News Views 195

Let’s not beat around the bush—Atos is doing something right in the sustainability game. They've bagged the EcoVadis Platinum Medal for five years running. Yep, that’s a serious flex in today’s corporate climate where ‘green’ isn’t just a buzzword; it’s almost an obligation if you want to stay relevant. The Metrics Behind Atos's Shine Scoring a...

Continue Reading
Power Metallic Mines Updates Shareholder Meeting Outcomes

Updated Category News Views 157

Power Metallic Mines Reports on AGSM Meeting Outcomes Power Metallic Mines Inc. (the "Company" or "Power Metallic") (TSXV: PNPN) (OTCBB: PNPNF) expressed satisfaction with the voting outcomes from its Annual General and Special Meeting ("AGSM") that took place recently. The meeting gathered shareholders to discuss essential business items and elect members to the Board of...

Continue Reading